Diagnosis and management of interstitial lung disease.

Translational respiratory medicine Pub Date : 2014-02-13 eCollection Date: 2014-01-01 DOI:10.1186/2213-0802-2-4
Keith C Meyer
{"title":"Diagnosis and management of interstitial lung disease.","authors":"Keith C Meyer","doi":"10.1186/2213-0802-2-4","DOIUrl":null,"url":null,"abstract":"<p><p>The complex tasks of making a confident diagnosis of a specific form of interstitial lung disease (ILD) and formulating a patient-centered, personalized management plan in an attempt to achieve remission or stabilization of the disease process can pose formidable challenges to clinicians. When patients are evaluated for suspected ILD, an accurate diagnosis of the specific form of ILD that a patient has developed must be made to provide the patient with useful prognostic information and to formulate an appropriate management plan that can relieve symptoms and restore or significantly improve quality of life. A well-performed patient history and physical examination provides invaluable information that can be combined with appropriate laboratory testing, imaging, and, if needed, tissue biopsy to reach a confident ILD diagnosis, and high-resolution computed tomography (HRCT) of the thorax is usually a key component of the diagnostic evaluation. If treatment is indicated, many forms of ILD can respond significantly to immunosuppressive anti-inflammatory therapies. However, ILD accompanied by extensive fibrosis may be difficult to treat, and the identification of an effective pharmacologic therapy for idiopathic pulmonary fibrosis (IPF) has remained elusive despite the completion of many phase 3 clinical trials over the past decade. Nonetheless, patients with IPF or advanced forms of non-IPF ILD can benefit significantly from detection and treatment of various co-morbid conditions that are often found in patients (especially the elderly patient), and supportive care (oxygen therapy, pulmonary rehabilitation) can have a beneficial impact on quality of life and symptom palliation. Finally, lung transplantation is an option for patients with progressive, advanced disease that does not respond to other therapies, but only a relatively small subset of patients with end-stage ILD are able to meet wait listing requirements and eventually undergo successful lung transplantation. </p>","PeriodicalId":90074,"journal":{"name":"Translational respiratory medicine","volume":"2 ","pages":"4"},"PeriodicalIF":0.0000,"publicationDate":"2014-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/2213-0802-2-4","citationCount":"128","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational respiratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/2213-0802-2-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 128

Abstract

The complex tasks of making a confident diagnosis of a specific form of interstitial lung disease (ILD) and formulating a patient-centered, personalized management plan in an attempt to achieve remission or stabilization of the disease process can pose formidable challenges to clinicians. When patients are evaluated for suspected ILD, an accurate diagnosis of the specific form of ILD that a patient has developed must be made to provide the patient with useful prognostic information and to formulate an appropriate management plan that can relieve symptoms and restore or significantly improve quality of life. A well-performed patient history and physical examination provides invaluable information that can be combined with appropriate laboratory testing, imaging, and, if needed, tissue biopsy to reach a confident ILD diagnosis, and high-resolution computed tomography (HRCT) of the thorax is usually a key component of the diagnostic evaluation. If treatment is indicated, many forms of ILD can respond significantly to immunosuppressive anti-inflammatory therapies. However, ILD accompanied by extensive fibrosis may be difficult to treat, and the identification of an effective pharmacologic therapy for idiopathic pulmonary fibrosis (IPF) has remained elusive despite the completion of many phase 3 clinical trials over the past decade. Nonetheless, patients with IPF or advanced forms of non-IPF ILD can benefit significantly from detection and treatment of various co-morbid conditions that are often found in patients (especially the elderly patient), and supportive care (oxygen therapy, pulmonary rehabilitation) can have a beneficial impact on quality of life and symptom palliation. Finally, lung transplantation is an option for patients with progressive, advanced disease that does not respond to other therapies, but only a relatively small subset of patients with end-stage ILD are able to meet wait listing requirements and eventually undergo successful lung transplantation.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
间质性肺疾病的诊断和治疗。
对特定形式的间质性肺疾病(ILD)做出可靠的诊断,并制定以患者为中心的个性化治疗计划,试图实现疾病缓解或稳定,这一复杂的任务对临床医生构成了巨大的挑战。当对疑似ILD的患者进行评估时,必须对患者已发展的ILD的特定形式进行准确诊断,以便为患者提供有用的预后信息,并制定适当的管理计划,以缓解症状,恢复或显着改善生活质量。良好的病史和体格检查可提供宝贵的信息,可与适当的实验室检查、影像学检查以及必要时的组织活检相结合,以获得可靠的ILD诊断,而胸部高分辨率计算机断层扫描(HRCT)通常是诊断评估的关键组成部分。如果需要治疗,许多类型的ILD对免疫抑制抗炎治疗有显著反应。然而,伴有广泛纤维化的ILD可能难以治疗,尽管在过去十年中完成了许多3期临床试验,但特发性肺纤维化(IPF)的有效药物治疗仍然难以捉摸。尽管如此,IPF患者或晚期非IPF型ILD患者可以从患者(尤其是老年患者)经常发现的各种合并症的检测和治疗中显著受益,支持性护理(氧疗、肺康复)可以对生活质量和症状缓解产生有益的影响。最后,肺移植是对其他治疗无效的进行性晚期疾病患者的一种选择,但只有相对较小的终末期ILD患者能够满足等待列表要求并最终成功进行肺移植。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The epidermal growth factor receptor (EGRF) in lung cancer. Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study. Response of airway epithelial cells to double-stranded RNA in an allergic environment. Serial pulmonary function tests to diagnose COPD in chronic heart failure. Expression of transcript factors SALL4 and OCT4 in a subset of non-small cell lung carcinomas (NSCLC).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1